These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 21166831)
21. Discovery of novel inhibitors targeting enoyl-acyl carrier protein reductase in Plasmodium falciparum by structure-based virtual screening. Nicola G; Smith CA; Lucumi E; Kuo MR; Karagyozov L; Fidock DA; Sacchettini JC; Abagyan R Biochem Biophys Res Commun; 2007 Jul; 358(3):686-91. PubMed ID: 17509532 [TBL] [Abstract][Full Text] [Related]
22. Prioritization of active antimalarials using structural interaction profile of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR)-triclosan derivatives. Kumar SP; George LB; Jasrai YT; Pandya HA SAR QSAR Environ Res; 2015; 26(1):61-77. PubMed ID: 25567142 [TBL] [Abstract][Full Text] [Related]
23. An Efficient and Economical Assay to Screen for Triclosan Binding to FabI. Demissie RD; Kabre P; Tuntland ML; Fung LW J Biomol Screen; 2016 Apr; 21(4):391-8. PubMed ID: 26538431 [TBL] [Abstract][Full Text] [Related]
24. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus. Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562 [TBL] [Abstract][Full Text] [Related]
25. Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides. Muench SP; Stec J; Zhou Y; Afanador GA; McPhillie MJ; Hickman MR; Lee PJ; Leed SE; Auschwitz JM; Prigge ST; Rice DW; McLeod R Bioorg Med Chem Lett; 2013 Jun; 23(12):3551-5. PubMed ID: 23664871 [TBL] [Abstract][Full Text] [Related]
26. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. Heath RJ; Rubin JR; Holland DR; Zhang E; Snow ME; Rock CO J Biol Chem; 1999 Apr; 274(16):11110-4. PubMed ID: 10196195 [TBL] [Abstract][Full Text] [Related]
27. Epigallocatechin gallate is a slow-tight binding inhibitor of enoyl-ACP reductase from Plasmodium falciparum. Banerjee T; Sharma SK; Surolia N; Surolia A Biochem Biophys Res Commun; 2008 Dec; 377(4):1238-42. PubMed ID: 18992222 [TBL] [Abstract][Full Text] [Related]
28. Design, development, synthesis, and docking analysis of 2'-substituted triclosan analogs as inhibitors for Plasmodium falciparum enoyl-ACP reductase. Kapoor N; Banerjee T; Babu P; Maity K; Surolia N; Surolia A IUBMB Life; 2009 Nov; 61(11):1083-91. PubMed ID: 19859979 [TBL] [Abstract][Full Text] [Related]
29. Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives. Freundlich JS; Anderson JW; Sarantakis D; Shieh HM; Yu M; Valderramos JC; Lucumi E; Kuo M; Jacobs WR; Fidock DA; Schiehser GA; Jacobus DP; Sacchettini JC Bioorg Med Chem Lett; 2005 Dec; 15(23):5247-52. PubMed ID: 16198563 [TBL] [Abstract][Full Text] [Related]
31. Structural basis for triclosan and NAD binding to enoyl-ACP reductase of Plasmodium falciparum. Suguna K; Surolia A; Surolia N Biochem Biophys Res Commun; 2001 Apr; 283(1):224-8. PubMed ID: 11322792 [TBL] [Abstract][Full Text] [Related]
32. Potent antimicrobial action of triclosan-lysozyme complex against skin pathogens mediated through drug-targeted delivery mechanism. Hoq MI; Ibrahim HR Eur J Pharm Sci; 2011 Jan; 42(1-2):130-7. PubMed ID: 21078387 [TBL] [Abstract][Full Text] [Related]
33. Importance of sigma factor mutations in increased triclosan resistance in Salmonella Typhimurium. Gantzhorn MR; Olsen JE; Thomsen LE BMC Microbiol; 2015 May; 15():105. PubMed ID: 25986727 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analogues. Sivaraman S; Sullivan TJ; Johnson F; Novichenok P; Cui G; Simmerling C; Tonge PJ J Med Chem; 2004 Jan; 47(3):509-18. PubMed ID: 14736233 [TBL] [Abstract][Full Text] [Related]
35. A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase. Levy CW; Baldock C; Wallace AJ; Sedelnikova S; Viner RC; Clough JM; Stuitje AR; Slabas AR; Rice DW; Rafferty JB J Mol Biol; 2001 May; 309(1):171-80. PubMed ID: 11491286 [TBL] [Abstract][Full Text] [Related]
36. Enoyl-ACP reductase (FabI) of Haemophilus influenzae: steady-state kinetic mechanism and inhibition by triclosan and hexachlorophene. Marcinkeviciene J; Jiang W; Kopcho LM; Locke G; Luo Y; Copeland RA Arch Biochem Biophys; 2001 Jun; 390(1):101-8. PubMed ID: 11368521 [TBL] [Abstract][Full Text] [Related]
40. Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade. Holas O; Ondrejcek P; Dolezal M J Enzyme Inhib Med Chem; 2015; 30(4):629-48. PubMed ID: 25383419 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]